Semaglutide is indicated for adults with type 2 diabetes mellitus (T2DM) who are receiving metformin and/or sulfonylureas in addition to diet control and exercise and whose blood glucose remains poorly controlled; For reducing the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) in adults with T2DM with cardiovascular disease.
Semaglutide is a GLP-1 receptor agonist utilized in pharmaceutical manufacturing. Its core synthesis involves solid-phase peptide chemistry. The molecular formula is C37H69N11O12, with CAS No. 910463-68-2.
Contraindicated in patients with a personal or family history of medullary thyroid carcinoma. Strictly store at 2°C to 8°C to maintain stability and prevent degradation of the peptide structure.